Bioresorbable scaffold technologies

Circulation Journal

Volumn 75, Issue 3, 2011, Pages 509-520

  Onuma, Yosinobu ^a   Ormiston, John ^b   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Bioresorbable scaffold; Coronary angiography; Coronary artery disease

Indexed keywords

POLYLACTIC ACID; RAPAMYCIN;

BARE METAL STENT; BIODEGRADABILITY; BIODEGRADATION; BIORESORBABLE SCAFFOLD; CITRIC ACID CYCLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DEPOLYMERIZATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ELASTICITY; HUMAN; HYDROLYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PROCESS TECHNOLOGY; REVIEW; STENT THROMBOSIS; TENSILE STRENGTH;

ABSORBABLE IMPLANTS; ANGIOPLASTY, BALLOON, CORONARY; BIOTECHNOLOGY; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; HUMANS; TISSUE SCAFFOLDS;

EID: 79952350783     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1135     Document Type: Review

References (81)

1. Zartner P, Cesnjevar R, Singer H, Weyand M. First successful implantation of a biodegradable metal stent into the left pulmonary artery of a preterm baby. Catheter Cardiovasc Interv 2005; 66: 590-594.
2. Saito Y, Tanaka T, Andoh A, Minematsu H, Hata K, Tsujikawa T, et al. Novel biodegradable stents for benign esophageal strictures following endoscopic submucosal dissection. Dig Dis Sci 2008; 53: 330-333.
3. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000; 102: 399-404.
4. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet 2008; 371: 899-907.
5. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910.
6. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial. Lancet 2007; 369: 1869-1875.
7. Gruentzig AR, King SB 3rd, Schlumpf M, Siegenthaler W. Longterm follow-up after percutaneous transluminal coronary angioplasty: The early Zurich experience. N Engl J Med 1987; 316: 1127-1132.
8. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, et al. Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon: A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77: 361-371.
9. Di Mario C, Gil R, Camenzind E, Ozaki Y, von Birgelen C, Umans V, et al. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol 1995; 75: 772-777.
10. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, et al. Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study. Circulation 1996; 94: 35-43.
11. Rodriguez AE, Santaera O, Larribau M, Fernandez M, Sarmiento R, Perez B, et al. Coronary stenting decreases restenosis in lesions with early loss in luminal diameter 24 hours after successful PTCA. Circulation 1995; 91: 1397-1402.
12. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I: Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327-333.
13. Nobuyoshi M, Kimura T, Ohishi H, Horiuchi H, Nosaka H, Hamasaki N, et al. Restenosis after percutaneous transluminal coronary angioplasty: Pathologic observations in 20 patients. J Am Coll Cardiol 1991; 17: 433-439.
14. Garratt KN, Edwards WD, Kaufmann UP, Vlietstra RE, Holmes DR Jr. Differential histopathology of primary atherosclerotic and restenotic lesions in coronary arteries and saphenous vein bypass grafts: Analysis of tissue obtained from 73 patients by directional atherectomy. J Am Coll Cardiol 1991; 17: 442-448.
15. Ormiston JA, Stewart FM, Roche AH, Webber BJ, Whitlock RM, Webster MW. Late regression of the dilated site after coronary angioplasty: A 5-year quantitative angiographic study. Circulation 1997; 96: 468-474.
16. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med 1994; 331: 489-495.
17. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501.
18. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: 2007-2011.
19. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109: 190-195.
20. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
21. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
22. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52: 1134-1140.
23. Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice MC, et al; ARTS II Investigators. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol 2010; 55: 1093-1101.
24. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006; 27: 166-170.
25. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005; 46: 231-236.
26. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: A cause for concern. Circulation 2007; 115: 1440-1455.
27. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.
28. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019.
29. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et al. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53: 1399-1409.
30. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352-356.
31. van Beusekom HM, Sorop O, van den Heuvel M, Onuma Y, Duncker DJ, Danser AH, et al. Endothelial function rather than endothelial restoration is altered in paclitaxel-as compared to bare metal-, sirolimusand tacrolimus-eluting stents. EuroIntervention 2010; 6: 117-125.
32. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, et al. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510.
33. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
34. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 2008; 372: 1163-1173.
35. Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The NOBORI 1 trial--Phase 2. Circ Cardiovasc Interv 2009; 2: 188-195.
36. Rajtar A, Kaluza GL, Yang Q, Hakimi D, Liu D, Tsui M, et al. Hydroxyapatite-coated cardiovascular stents. EuroIntervention 2006; 2: 113-115.
37. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12: 616-623.
38. Kaltenbach M, Kober G, Scherer D, Vallbracht C. Recurrence rate after successful coronary angioplasty. Eur Heart J 1985; 6: 276-281.
39. Leimgruber PP, Roubin GS, Hollman J, Cotsonis GA, Meier B, Douglas JS, et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 1986; 73: 710-717.
40. Kimura T, Kaburagi S, Tamura T, Yokoi H, Nakagawa Y, Hamasaki N, et al. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation 1997; 96: 475-483.
41. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study. Circulation 1996; 94: 1247-1254.
42. Luo H, Nishioka T, Eigler NL, Forrester JS, Fishbein MC, Berglund H, et al. Coronary artery restenosis after balloon angioplasty in humans is associated with circumferential coronary constriction. Arterioscler Thromb Vasc Biol 1996; 16: 1393-1398.
43. Babalik E, Gulbaran M, Gurmen T, Ozturk S. Fracture of popliteal artery stents. Circ J 2003; 67: 643-645.
44. Eggebrecht H, Rodermann J, Hunold P, Schmermund A, Bose D, Haude M, et al. Images in cardiovascular medicine: Novel magnetic resonance-compatible coronary stent: The absorbable magnesiumalloy stent. Circulation 2005; 112: e303-e304.
45. DiMario C, Borgia F. Assimilating the curren tclinical data of fully bioabsorbable stents. Eurointervention 2009; 5: F103-F108.
46. van der Giessen WJ, Slager CJ, van Beusekom HM, van Ingen Schenau DS, Huijts RA, Schuurbiers JC, et al. Development of a polymer endovascular prosthesis and its implantation in porcine arteries. J Interv Cardiol 1992; 5: 175-185.
47. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-1677.
48. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997; 29: 808-816.
49. Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E, et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 1998; 32: 780-786.
50. English JP, Perrin DE. Polyglycolide and polylactide. In: Wiseman DM, Kost J, Domb AJ, editors. Handbook of biodegradable polymers. CRC Press, 1998.
51. Kronenthal R. Biodegradable polymers in medicine and surgery. In: Kronenthal R, Oser Z, Martin E, editors. Polymers in medicine and surgery. New York: Plenum Press, 1975; 119-137.
52. Hollinger JO, Battistone GC. Biodegradable bone repair materials: Synthetic polymers and ceramics. Clin Orthop Relat Res 1986; (207): 290-305.
53. Nishio S. Long-term (>10 years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents. In: EuroPCR. Paris, 2010.
54. Post MJ, de Graaf-Bos AN, van Zanten HG, de Groot PG, Sixma JJ, Borst C. Thrombogenicity of the human arterial wall after interventional thermal injury. J Vasc Res 1996; 33: 156-163.
55. Biamino G, Schmidt A, Scheinert D. Treatment of SFA lesions with PLLA biodegradable stents: Results of the PERSEUS study. J Endovasc Ther 2005; 12(Suppl): 5.
56. Tanimoto S, Bruining N, van Domburg RT, Rotger D, Radeva P, Ligthart JM, et al. Late stent recoil of the bioabsorbable everolimuseluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol 2008; 52: 1616-1620.
57. Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT Trials. Cathet Cardiovasc Interv 2007; 70: 515-523.
58. Onuma Y, Serruys P, Ormiston J, Regar E, Webster M, Thuesen L, et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: The ABSORB trial. EuroIntervention 2010; 6: 447-453.
59. Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005; 1: 58-65.
60. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, et al. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. Eurointervention 2006; 2: 286-294.
61. Onuma Y, Serruys P, Perkins L, Okamura T, Gonzalo N, Garcia-Garcia HM, et al. Intracoronary optical coherence tomography (OCT) and histology at 1 month, at 2, 3 and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: An attempt to decipher the human OCT images in the ABSORB trial. Circulation 2010 (in press).
62. Okamura T, Garg S, Gutiérrez-Chico J, Shin E, Onuma Y, García-García H, et al. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: An OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention 2010; 5: 932-938.
63. Serruys PW, Onuma Y, Ormiston JA, Bruyne BD, Regar E, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis six-month clinical and imaging outcomes. Circulation 2010 (in press).
64. Schulze R. REVA Medical, Inc. Bioresorbable stent. In: Cardiovascular revascularization therapies 2007; 2007.
65. Grube E. Bioabsorbable stent. The Boston Scientific and REVA technology. In: EuroPCR 2009. Barcelona; 2009.
66. Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. EuroIntervention 2009; 5(Suppl F): F58-F64.
67. Barlis P, Tanigawa J, Di Mario C. Coronary bioabsorbable magnesium stent: 15-month intravascular ultrasound and optical coherence tomography findings. Eur Heart J 2007; 28: 2319.
68. Ghimire G, Spiro J, Kharbanda R, Roughton M, Barlis P, Mason M, et al. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention 2009; 4: 481-484.
69. Waksman R, Erbel R, Di Mario C, Bartunek J, de Bruyne B, Eberli FR, et al. Early-and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc Interv 2009; 2: 312-320.
70. Peuster M, Wohlsein P, Brugmann M, Ehlerding M, Seidler K, Fink C, et al. A novel approach to temporary stenting: Degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits. Heart 2001; 86: 563-569.
71. Peuster M, Hesse C, Schloo T, Fink C, Beerbaum P, von Schnakenburg C. Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. Biomaterials 2006; 27: 4955-4962.
72. Pendyala LK, Yin X, Li J, Chen JP, Chronos N, Hou D. The firstgeneration drug-eluting stents and coronary endothelial dysfunction. JACC Cardiovasc Interv 2009; 2: 1169-1177.
73. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-658.
74. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.
75. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993; 328: 1659-1664.
76. Doucette JW, Corl PD, Payne HM, Flynn AE, Goto M, Nassi M, et al. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation 1992; 85: 1899-1911.
77. Serruys PW, Zijlstra F, Laarman GJ, Reiber HH, Beatt K, Roelandt J. A comparison of two methods to measure coronary flow reserve in the setting of coronary angioplasty: Intracoronary blood flow velocity measurements with a Doppler catheter, and digital subtraction cineangiography. Eur Heart J 1989; 10: 725-736.
78. Bruining N, Tanimoto S, Otsuka M, Weustink A, Ligthart J, de Winter S, et al. Quantitative multi-modality imaging analysis of a bioabsorbable poly-L-lactic acid stent design in the acute phase: A comparison between 2-and 3D-QCA, QCU and QMSCT-CA. EuroIntervention 2008; 4: 285-291.
79. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007; 370: 937-948.
80. Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. Euro-Intervention 2009; 5(Suppl F): F15-F22.
81. Garg S, Serruys P. Biodegradable stents and non-biodegradable stents. Minerva Cardioangiol 2009; 57: 537-565.